Colchicine 0.6 mg Capsules Delivered to Your Door

colchicine 0.6 mg capsules delivered to your door

Hate making the trip to your local pharmacy to pick up your prescriptions? Here’s some good news: if you take colchicine to prevent gout attacks, you can get Mitigare® (Colchicine) 0.6 mg Capsules or Generic Colchicine 0.6 mg Capsules delivered right to your door.1 Read on to find out more about this complimentary service and how you may be able to save money on your colchicine therapy.

 

Request home delivery

Home delivery of Mitigare® or Generic Colchicine Capsules is simple, convenient and available at no cost to patients. To request this service, print and complete the Patient Information and Insurance Information sections of the Mitigare® Delivery Form. Give your completed form to your physician, and he or she will send your prescription(s) to EVERSANA Life Services Pharmacy for direct delivery to your home. Once EVERSANA Life Services Pharmacy receives your information, they will contact you to confirm the details and set up your home delivery. It’s that simple!

 

Get refills and reminders

Additional services are available to patients who are signed up for home delivery of Mitigare® or Generic Colchicine Capsules. It’s simple to request automatic refills and/or refill reminders—services that make it even easier to get the medications you need—and you can cancel anytime.

  • Automatic refills—When you sign up for home delivery of Mitigare® or Generic Colchicine mg Capsules, you can choose to have your prescription automatically refilled each month.
  • Refill reminders—If you are a home delivery customer and don’t opt for automatic refills, you can set up a monthly reminder to request a refill of your Mitigare® or Generic Colchicine 0.6 mg Capsules. You can even choose to receive your reminder via your preferred method of communication—automated phone call, email or text message.

 

Visit your pharmacy

If you prefer to purchase colchicine from a neighborhood drugstore, you’ll find that many local and chain stores carry Mitigare® and/or Generic Colchicine Capsules. If you’re new to your area, call Mitigare® Customer Service. They’ll be happy to help you find a local pharmacy that carries Mitigare® or Generic Colchicine Capsules.

 

Save money on colchicine therapy

If you’ve been taking Mitigare® for a while, you may have heard of the True Blue Savings Program. With the Mitigare® True Blue Savings Card, eligible patients can receive Mitigare® or Generic Colchicine 0.6 mg Capsules for as little as $0 for the first 30 days and refills for as low as $5.* To find out more about the True Blue Savings Program and to download a True Blue Savings Card, click here.

 

*For all eligible patients 18 years or older who are legal residents of the United States or Puerto Rico. First 30 days are as little as $0 only for eligible patients. Maximum savings of $65 on the first fill and $50 on refills. Please see complete Terms and Conditions available at Mitigare.com.

 

Mitigare® is a registered trademark of Hikma Pharmaceuticals USA Inc.

 

Colchicine 0.6 mg capsules are contraindicated in patients with renal or hepatic impairment who are currently prescribed drugs that inhibit both P-gp and CYP3A4. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment has resulted in life-threatening or fatal colchicine toxicity. Patients with both renal and hepatic impairment should not be given Mitigare®.

Fatal overdoses have been reported with colchicine in adults and children. Keep Mitigare® out of the reach of children.

Blood dyscrasias such as myelosuppression, leukopenia, granulocytopenia, thrombocytopenia and aplastic anemia have been reported with colchicine used in therapeutic doses.

Monitor for toxicity and, if present, consider temporary interruption or discontinuation of colchicine.

Drug interaction with dual P-gp and CYP3A4 inhibitors: Co-administration of colchicine with dual P-gp and CYP3A4 inhibitors has resulted in life-threatening interactions and death.

Neuromuscular toxicity and rhabdomyolysis may occur with chronic treatment with colchicine in therapeutic doses, especially in combination with other drugs known to cause this effect. Patients with impaired renal function and elderly patients (including those with normal renal and hepatic function) are at increased risk. Consider temporary interruption or discontinuation of Mitigare®.

The most commonly reported adverse reactions with colchicine are gastrointestinal symptoms, including diarrhea, nausea, vomiting and abdominal pain.

 

Please see the full Prescribing Information and Medication Guide for Mitigare® for complete product details.

 

NOTE: This article was not written by a medical professional and is not intended to substitute for the guidance of a physician. These are not Hikma’s recommendations for gout flare prevention, but rather facts and data collected from various reliable medical sources. For a full list of resources and their attributing links, see below.

Important Safety Information for Mitigare® (colchicine) 0.6 mg capsules

  • Colchicine 0.6 mg capsules are contraindicated in patients with renal or hepatic impairment who are currently prescribed drugs that inhibit both P-gp and CYP3A4. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment has resulted in life-threatening or fatal colchicine toxicity. Patients with both renal and hepatic impairment should not be given Mitigare®.
  • Fatal overdoses have been reported with colchicine in adults and children. Keep Mitigare® out of the reach of children.
  • Blood dyscrasias such as myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, and aplastic anemia have been reported with colchicine used in therapeutic doses.
  • Monitor for toxicity and if present consider temporary interruption or discontinuation of colchicine.
  • Drug interaction with dual P-gp and CYP3A4 inhibitors: Co-administration of colchicine with dual P-gp and CYP3A4 inhibitors has resulted in life-threatening interactions and death.
  • Neuromuscular toxicity and rhabdomyolysis may occur with chronic treatment with colchicine in therapeutic doses, especially in combination with other drugs known to cause this effect. Patients with impaired renal function and elderly patients (including those with normal renal and hepatic function) are at increased risk. Consider temporary interruption or discontinuation of Mitigare®.
  • The most commonly reported adverse reactions with colchicine are gastrointestinal symptoms, including diarrhea, nausea, vomiting, and abdominal pain.

Indication

Mitigare® is indicated for prophylaxis of gout flares in adults. The safety and effectiveness of Mitigare for acute treatment of gout flares during prophylaxis has not been studied.

Mitigare® is not an analgesic medication and should not be used to treat pain from other causes.

For Full Prescribing Information please CLICK HERE and for Medication Guide CLICK HERE.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Manufactured by: West-Ward Columbus Inc., Columbus, OH 43228

Important Safety Information for Mitigare® (colchicine) 0.6 mg capsules

  • Colchicine 0.6 mg capsules are contraindicated in patients with renal or hepatic impairment who are currently prescribed drugs that inhibit both P-gp and CYP3A4.